Merchant Mark - Cell Signaling Pathways & Translat Oncol, Genentech Inc

基本信息

浏览量：38

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 27 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Supplementary Data from IRE1α Disruption in Triple-Negative Breast Cancer Cooperates with Antiangiogenic Therapy by Reversing ER Stress Adaptation and Remodeling the Tumor Microenvironment

Jonathan M. Harnoss,Adrien Le Thomas,Mike Reichelt,Ofer Guttman,Thomas D. Wu,Scot A. Marsters, Anna Smerdel-Ramoya, David Lawrence,David Kan,Ehud Segal,Mark Merchant,Klára Tótpál,Lisa Crocker,Kathryn Mesh,Monika Dohse,Margaret Solon,Zora Modrušan,Joachim Rudolph, Hartmut Koeppen, Peter Wipf,Avi Ashkenazi

openalex（2023）

引用0浏览0引用

Supplementary Figure 2 from HGF As a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors

Elicia Penuel, Congfen Li, Vaishali Parab, Luciana Burton, Kyra J. Cowan,Mark Merchant, Robert L. Yauch, Premal Patel,Amy Peterson, Garret M. Hampton, Mark R. Lackner, Priti S. Hegde

openalex（2023）

引用0浏览0引用

Supplementary Figure Legends from Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer

Lingyan Jin, Jesse Garcia, Emily Chan, Cecile de la Cruz,Ehud Segal,Mark Merchant, Samir Kharbanda, Ryan Raisner, Peter M. Haverty,Zora Modrušan, Justin Q. Ly, Edna F. Choo, Susan Kaufman, Maureen H. Beresini, F. Anthony Romero, Steven Magnuson, Karen E. Gascoigne

openalex（2023）

引用0浏览0引用

Supplementary Figure 1 from HGF As a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors